<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00666835</url>
  </required_header>
  <id_info>
    <org_study_id>2003-29-INJ-9</org_study_id>
    <nct_id>NCT00666835</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients</brief_title>
  <official_title>Randomized, Double-blind, Multicenter, Parallel-group, Equivalence Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hexal AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, multicenter, parallel-group, equivalence study involving
      about 462 clinically stable hemodialysis patients aged 18 years or above suffering from
      anemia and treated previously with a stable dose of ERYPO® intravenously.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this Phase III study is the evaluation of therapeutic equivalence of
      HX575 Hexal AG and a comparator of epoetin alfa, ERYPO® in the maintenance intravenous
      treatment of renal anemia. Efficacy, dosage and safety of HX575 Hexal AG in the long-term
      treatment were assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2004</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Compare the Efficacy of HX575 Hexal AG and ERYPO® Janssen-Cilag.</measure>
    <time_frame>28 weeks</time_frame>
    <description>Primary endpoint was the mean absolute change in Hb level between the screening/baseline and the evaluation period. A two-sided 95 % confidence interval for the difference in mean change (mean of evaluation period - mean of screening/baseline period) in Hb between epoetin alfa HX575 Hexal AG and ERYPO® Janssen-Cilag was computed. The difference was estimated from an analysis of a co-variance model including factors treatment, center, mean baseline Hb (&lt;11.5 and ≥11.5 g/dL) as factors and change of the mean weekly dose from screening/baseline to the evaluation period (of HX575 epoetin alfa Hexal AG or ERYPO® Janssen-Cilag) as a covariate. HX575 Hexal AG was considered at least as good as ERYPO® Janssen-Cilag if the 95 % confidence interval of the difference in mean changes in Hb levels between HX575 Hexal AG and ERYPO® Janssen-Cilag lied entirely within the interval [-0.5 g/dL; 0.5 g/dL]. Primary Endpoint was analyzed based on intent-to-treat (ITT) population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Change in Hemoglobin Level From the Screening/Baseline Period to the Evaluation Period - ITT Population</measure>
    <time_frame>28 weeks</time_frame>
    <description>The mean absolute change in Hb levels between the screening/baseline period and the evaluation period was analyzed for the intent-to-treat (ITT) population in the same way as the primary efficacy endpoint. A two-sided 95 % confidence interval for the difference in mean change (mean of evaluation period - mean of screening/baseline period) in Hb between HX575 epoetin alfa Hexal AG and ERYPO® Janssen-Cilag was computed. The difference was estimated from an analysis of a co-variance model including factors treatment, center, mean baseline Hb (&lt;11.5 and ≥11.5 g/dL) as factors and change of the mean weekly dose from screening/baseline to the evaluation period (of HX575 epoetin alfa Hexal AG or ERYPO® Janssen-Cilag) as a covariate. HX575 Hexal AG was considered at least as good as ERYPO® Janssen-Cilag if the 95 % confidence interval of the difference in mean changes in Hb levels between HX575 Hexal AG and ERYPO® Janssen-Cilag lied entirely within the interval [-0.5 g/dL; 0.5 g/dL].</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">478</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>HX575 epoetin alfa Hexal AG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients were switched from the comparator ERYPO®, to epoetin alfa HX575 Hexal AG in ratio 2:1 to be intravenously treated with HX575 in pre-filled syringes for 24 weeks (solution for injection i.v.). The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ERYPO®, Janssen-Cilag</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible patients were randomized and continued to be treated with ERYPO® Janssen-Cilag in pre-filled syringes intravenously (solution for injection i.v.) for 24 weeks. The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HX575 epoetin alfa Hexal AG</intervention_name>
    <description>HX575 Solution for i.v. injection Containing 1000, 2000 and 4000 IU of rh erythropoietin</description>
    <arm_group_label>HX575 epoetin alfa Hexal AG</arm_group_label>
    <other_name>Binocrit, Abseamed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ERYPO®, Janssen-Cilag</intervention_name>
    <description>Solution for i.v. injection</description>
    <arm_group_label>ERYPO®, Janssen-Cilag</arm_group_label>
    <other_name>EPREX®</other_name>
    <other_name>Solution for i.v. injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Receiving dialysis for at least 6 months (3 times weekly) before screening

          -  Age: &gt;=18

          -  Clinically stable, i.e. hemoglobin within the established range (10.0 to 13.0 g/dl)
             for at least 12 weeks before screening

          -  Stable intravenous dosage of ERYPO® three times weekly for at least 8 weeks before
             screening and during screening with a maximal weekly dosage of 300 IU/kg body weight
             (stable is defined as &lt;25% change (up or down) in weekly dose and no change in
             frequency over 8 weeks prior screening and 10 weeks prior randomisation)

          -  Baseline hemoglobin concentration of 10.0 to 13.0 g/dl (mean of two pre-randomization
             pre-dialysis samples of Hb at visit -2 and visit 1)

          -  Serum ferritin &gt;=100 µg/l and/or saturated transferrin levels &gt;=20%

          -  C-reactive protein &lt;15 mg/l (&lt; 5 mg/l: normal; &gt;= 5 mg/l &lt; 10 mg/l: +; &gt;=10mg/l &lt; 100
             mg/l: ++; &gt;=100 mg/l: +++)

          -  Ability to follow study instructions and likely to complete all required visits

          -  Written informed consent of the patient

        Exclusion Criteria:

          -  Anemia of non-renal causes

          -  Primary hematologic disorder (e.g. myelodysplastic syndrome, sickle cell anemia,
             hematological malignancy, hemolytic anemia)

          -  Evidence of severe hepatic dysfunction (ALT and/or AST above 2 x upper limit of normal
             range; or gamma-GT above 3 x upper limit of normal range)

          -  Clinical evidence of current uncontrolled hyperparathyroidism (serum parathyroid
             hormone &gt;1500 pg/mL).

          -  Known history of bone marrow disease

          -  Any red blood cell transfusion(s) during the last 12 weeks before screening or during
             the screening/baseline period

          -  Insufficient concomitant iron treatment during the last 2 months before Visit -2

          -  Uncontrolled hypertension, defined as a predialysis diastolic blood pressure
             measurement &gt;=110 mmHg during the screening period

          -  Congestive heart failure [New York Heart Association (NYHA) class III and IV]

          -  Unstable angina pectoris, active cardiac disease, cardiac infarction during the last
             six months before screening

          -  History of blood coagulation disease

          -  Thrombocytopenia (platelet count &lt;100.000/µl)

          -  Leukopenia (white blood cell count &lt; 2.000/µl)

          -  Overt bleeding (acute or chronic bleeding within 2 months of inclusion) or hemolysis

          -  Evidence of acute infectious disease or serious active inflammatory states within one
             months before screening (Visit -2) or during the screening/baseline period

          -  Suspicion or known PRCA (pure red cell aplasia)

          -  Previously diagnosed HIV or acute hepatitis infection

          -  Treatment for epilepsy within the past 6 months

          -  Planned surgery during the next 7 months (except vascular access surgery)

          -  Any androgen therapy within 2 months before visit -2 and during the study

          -  Therapy with immunosuppressants or any drug known to affect the hematocrit within 1
             month before Visit -2 and during the study

          -  Clinical evidence of malignant diseases

          -  Pregnancy, breastfeeding women or women not using adequate birth control measures

          -  Known history of severe drug related allergies

          -  Known allergy to one of the ingredients of the test or reference products or
             hypersensitivity to mammalian-derived products

          -  Simultaneous participation in another clinical study or participation in a study in
             the month preceding the start of this study or previously randomized in this study

          -  Participation in an erythropoietin study in the 3 months preceding screening (visit
             -2)

          -  Any other condition which at the investigator´s discretion may put the patient at risk
             or which may confound the study results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne Haag-Weber, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dialysezentrum Straubing, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Landeskrankenhaus Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus der Barmherzigen Brüder Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialyseinstitut Graz GmbH</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Elisabethinen</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Innsbruck, Klinische Abteilung für Nephrologie</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Öffentliches Krankenhaus St. Pölten, I. Med. Abteilung</name>
      <address>
        <city>St. Poelten</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines öffentliches Krankenhaus Wiener Neustadt , 2. Interne Abteilung</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenanstalt Rudolfstiftung der Stadt Wien, 3. Med. Abteilung</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital der Stadt Wien, Abt. für Nephrologie und Dialyse</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysepraxis Bad Münder</name>
      <address>
        <city>Bad Münder</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Bamberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Bayreuth</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Bergisch Gladbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V.</name>
      <address>
        <city>Bischofswerda</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V.</name>
      <address>
        <city>Bremerhaven</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V.</name>
      <address>
        <city>Coburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysepraxis Drs. Riedasch/Schreiber</name>
      <address>
        <city>Coesfeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Deggendorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysepraxis</name>
      <address>
        <city>Donaueschingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Eberswalde</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysepraxis Dr. med. Stefan Holzmann</name>
      <address>
        <city>Erkelenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysepraxis Dr. Möller, Dr. Knee</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysepraxis</name>
      <address>
        <city>Freiberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Fürstenzell</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Guenzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Gummersbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dres. Sohn und Schaumann</name>
      <address>
        <city>Hameln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Haßfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysepraxis Dr. med. Stefan Holzmann</name>
      <address>
        <city>Heinsberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Kienle</name>
      <address>
        <city>Homberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Ingolstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH - Prof. Dr. med. Heide Sperschneider</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Kronach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysepraxis Dr. med. Matthias Anders</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kfh Kuratorium für Dialyse &amp; Nierentransplantation e.V., 2.Etage</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Nierentranplantation und Dialyse e.V.</name>
      <address>
        <city>Lohr</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysepraxis Prof. Rob, Dr. Wilhelm u. Dr. Schümann</name>
      <address>
        <city>Luebeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysepraxis Dr.med. H.-D. Hoffmann</name>
      <address>
        <city>Menden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Neuried</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Noerdlingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr.Steger, Dr.Böhmer, Dr.Kirpal</name>
      <address>
        <city>Nuremberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Oberschleißheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V.</name>
      <address>
        <city>Plauen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum</name>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dres.Hartmann, Schiele</name>
      <address>
        <city>Saarbruecken</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Straubing</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Sulzbach-Rosenberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2008</study_first_submitted>
  <study_first_submitted_qc>April 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2008</study_first_posted>
  <results_first_submitted>April 24, 2017</results_first_submitted>
  <results_first_submitted_qc>April 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 2, 2017</results_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment of anemia in hemodialysis patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 568 patients were screened. 479 were eligible for inclusion and were randomized. 478 patients were started on treatment with either epoetin alfa HX575 Hexal AG or ERYPO®, Janssen-Cilag. As the randomization followed a 2:1 scheme, 314 patients received HX575 Hexal AG and 164 patients received ERYPO®.</recruitment_details>
      <pre_assignment_details>The first part of the study was designed as a double-blind, randomized, multicenter, parallel-group equivalence study and consisted of two phases: Phase I (dose adjustment and maintenance of Hb level; until week 24) followed by Phase II (evaluation period: four week evaluation period to determine the primary efficacy endpoint; weeks 25 until 28).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>HX575 Epoetin Alfa Hexal AG</title>
          <description>Eligible patients were switched from the comparator to epoetin alfa HX575 Hexal AG in ratio 2:1. Treatment was done intravenously (solution for injection i.v.) in pre-filled syringes for 24 weeks. The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL. Baseline HB value after 24 weeks was required for efficacy analysis at week 28.</description>
        </group>
        <group group_id="P2">
          <title>ERYPO®, Janssen-Cilag</title>
          <description>Eligible patients were randomized and continued to be treated intravenously with ERYPO®, Janssen-Cilag in pre-filled syringes (solution for injection i.v.) for 24 weeks. The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL. Baseline HB value after 24 weeks was required for efficacy analysis at week 28.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="314"/>
                <participants group_id="P2" count="164"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="261"/>
                <participants group_id="P2" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incl./excl. not fulfilled</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Kidney Transplantation (NTX)</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hemoglobulin concentration</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Planned operation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized patients who received at least 1 dose of the study medication and for whom at least 1 post-baseline value of the primary endpoint Hb was available. A prerequisite for patients to be included in the Intention To Treat (ITT) population is that they were treated for four weeks with Hb values available during this period.</population>
      <group_list>
        <group group_id="B1">
          <title>HX575 Epoetin Alfa Hexal AG</title>
          <description>Eligible patients were switched from the comparator to HX575 epoetin alfa Hexal AG in ratio 2:1. Treatment was done intravenously (solution for injection i.v.) in pre-filled syringes for 24 weeks. The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL. Baseline HB value after 24 weeks was required for efficacy analysis at week 28.</description>
        </group>
        <group group_id="B2">
          <title>ERYPO®, Janssen-Cilag</title>
          <description>Eligible patients were randomized and continued to be treated with ERYPO® Janssen-Cilag intravenously in pre-filled syringes (solution for injection i.v.) for 24 weeks. The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL. Baseline HB value after 24 weeks was required for efficacy analysis at week 28.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="314"/>
            <count group_id="B2" value="164"/>
            <count group_id="B3" value="478"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="229"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.3" spread="14.4"/>
                    <measurement group_id="B2" value="62.6" spread="13.8"/>
                    <measurement group_id="B3" value="62.4" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="236"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="244"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.3" spread="15.5"/>
                    <measurement group_id="B2" value="76.0" spread="17.7"/>
                    <measurement group_id="B3" value="76.2" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Compare the Efficacy of HX575 Hexal AG and ERYPO® Janssen-Cilag.</title>
        <description>Primary endpoint was the mean absolute change in Hb level between the screening/baseline and the evaluation period. A two-sided 95 % confidence interval for the difference in mean change (mean of evaluation period – mean of screening/baseline period) in Hb between epoetin alfa HX575 Hexal AG and ERYPO® Janssen-Cilag was computed. The difference was estimated from an analysis of a co-variance model including factors treatment, center, mean baseline Hb (&lt;11.5 and ≥11.5 g/dL) as factors and change of the mean weekly dose from screening/baseline to the evaluation period (of HX575 epoetin alfa Hexal AG or ERYPO® Janssen-Cilag) as a covariate. HX575 Hexal AG was considered at least as good as ERYPO® Janssen-Cilag if the 95 % confidence interval of the difference in mean changes in Hb levels between HX575 Hexal AG and ERYPO® Janssen-Cilag lied entirely within the interval [–0.5 g/dL; 0.5 g/dL]. Primary Endpoint was analyzed based on intent-to-treat (ITT) population.</description>
        <time_frame>28 weeks</time_frame>
        <population>Primary Endpoint was analyzed based on ITT population: all treated patients with a post baseline hemoglobin value.</population>
        <group_list>
          <group group_id="O1">
            <title>HX575 Epoetin Alfa Hexal AG</title>
            <description>Eligible patients were switched from the comparator to HX575 epoetin alfa Hexal AG in ratio 2:1. Treatment was done intravenously (solution for injection i.v.) in pre-filled syringes for 24 weeks. The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL. Baseline HB value after 24 weeks was required for efficacy analysis at week 28.</description>
          </group>
          <group group_id="O2">
            <title>ERYPO®, Janssen-Cilag</title>
            <description>Eligible patients were randomized and continued to be treated with ERYPO®, Janssen-Cilag in pre-filled syringes intravenously (solution for injection i.v.) for 24 weeks. The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL. Baseline HB value after 24 weeks was required for efficacy analysis at week 28.</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Efficacy of HX575 Hexal AG and ERYPO® Janssen-Cilag.</title>
          <description>Primary endpoint was the mean absolute change in Hb level between the screening/baseline and the evaluation period. A two-sided 95 % confidence interval for the difference in mean change (mean of evaluation period – mean of screening/baseline period) in Hb between epoetin alfa HX575 Hexal AG and ERYPO® Janssen-Cilag was computed. The difference was estimated from an analysis of a co-variance model including factors treatment, center, mean baseline Hb (&lt;11.5 and ≥11.5 g/dL) as factors and change of the mean weekly dose from screening/baseline to the evaluation period (of HX575 epoetin alfa Hexal AG or ERYPO® Janssen-Cilag) as a covariate. HX575 Hexal AG was considered at least as good as ERYPO® Janssen-Cilag if the 95 % confidence interval of the difference in mean changes in Hb levels between HX575 Hexal AG and ERYPO® Janssen-Cilag lied entirely within the interval [–0.5 g/dL; 0.5 g/dL]. Primary Endpoint was analyzed based on intent-to-treat (ITT) population.</description>
          <population>Primary Endpoint was analyzed based on ITT population: all treated patients with a post baseline hemoglobin value.</population>
          <units>g/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.147" spread="0.092"/>
                    <measurement group_id="O2" value="0.063" spread="0.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Therapeutic equivalence was defined as the two-sided 95 % confidence interval of the difference between the two treatment groups lying entirely in the interval –0.5 to 0.5 g/dL. The confidence interval of the difference was calculated based on the least square means (LSMEANS) from an analysis of co-variance model including factors treatment, center, mean baseline Hb level (&lt;11.5 and T11.5 g/dL) as factors and change of the mean weekly dose as a covariate.</non_inferiority_desc>
            <param_type>Point estimate of difference (ANCOVA)</param_type>
            <param_value>0.084</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.170</ci_lower_limit>
            <ci_upper_limit>0.338</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Absolute Change in Hemoglobin Level From the Screening/Baseline Period to the Evaluation Period - ITT Population</title>
        <description>The mean absolute change in Hb levels between the screening/baseline period and the evaluation period was analyzed for the intent-to-treat (ITT) population in the same way as the primary efficacy endpoint. A two-sided 95 % confidence interval for the difference in mean change (mean of evaluation period - mean of screening/baseline period) in Hb between HX575 epoetin alfa Hexal AG and ERYPO® Janssen-Cilag was computed. The difference was estimated from an analysis of a co-variance model including factors treatment, center, mean baseline Hb (&lt;11.5 and ≥11.5 g/dL) as factors and change of the mean weekly dose from screening/baseline to the evaluation period (of HX575 epoetin alfa Hexal AG or ERYPO® Janssen-Cilag) as a covariate. HX575 Hexal AG was considered at least as good as ERYPO® Janssen-Cilag if the 95 % confidence interval of the difference in mean changes in Hb levels between HX575 Hexal AG and ERYPO® Janssen-Cilag lied entirely within the interval [-0.5 g/dL; 0.5 g/dL].</description>
        <time_frame>28 weeks</time_frame>
        <population>Intent-to-treat population (ITT): all randomized patients who received at least one dose of the study medication and for whom at least one post-baseline value of the primary endpoint Hb was available. A prerequisite to be included in the ITT population was that they were treated for four weeks with Hb values available during this period.</population>
        <group_list>
          <group group_id="O1">
            <title>HX575 Epoetin Alfa Hexal AG</title>
            <description>Eligible patients were switched from the comparator to HX575 epoetin alfa Hexal AG in ratio 2:1. Treatment was done intravenously (solution for injection i.v.) in pre-filled syringes for 24 weeks. The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL. Baseline HB value after 24 weeks was required for efficacy analysis at week 28.</description>
          </group>
          <group group_id="O2">
            <title>ERYPO®, Janssen-Cilag</title>
            <description>Eligible patients were randomized and continued to be treated intravenously with ERYPO® Janssen-Cilag in pre-filled syringes (solution for injection i.v.) for 24 weeks. The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL. Baseline HB value after 24 weeks was required for efficacy analysis at week 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute Change in Hemoglobin Level From the Screening/Baseline Period to the Evaluation Period - ITT Population</title>
          <description>The mean absolute change in Hb levels between the screening/baseline period and the evaluation period was analyzed for the intent-to-treat (ITT) population in the same way as the primary efficacy endpoint. A two-sided 95 % confidence interval for the difference in mean change (mean of evaluation period - mean of screening/baseline period) in Hb between HX575 epoetin alfa Hexal AG and ERYPO® Janssen-Cilag was computed. The difference was estimated from an analysis of a co-variance model including factors treatment, center, mean baseline Hb (&lt;11.5 and ≥11.5 g/dL) as factors and change of the mean weekly dose from screening/baseline to the evaluation period (of HX575 epoetin alfa Hexal AG or ERYPO® Janssen-Cilag) as a covariate. HX575 Hexal AG was considered at least as good as ERYPO® Janssen-Cilag if the 95 % confidence interval of the difference in mean changes in Hb levels between HX575 Hexal AG and ERYPO® Janssen-Cilag lied entirely within the interval [-0.5 g/dL; 0.5 g/dL].</description>
          <population>Intent-to-treat population (ITT): all randomized patients who received at least one dose of the study medication and for whom at least one post-baseline value of the primary endpoint Hb was available. A prerequisite to be included in the ITT population was that they were treated for four weeks with Hb values available during this period.</population>
          <units>g/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" spread="0.079"/>
                    <measurement group_id="O2" value="-0.187" spread="0.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Therapeutic equivalence was defined as the two-sided 95 % confidence interval of the difference between the two treatment groups lying entirely in the interval –0.5 to 0.5 g/dL. The confidence interval of the difference was calculated based on the least square means (LSMEANS) from an analysis of co-variance model including factors treatment, center, mean baseline Hb level (&lt;11.5 and T11.5 g/dL) as factors and change of the mean weekly dose as a covariate.</non_inferiority_desc>
            <param_type>Difference LSM of Epo Hexal &amp; Erypo</param_type>
            <param_value>0.189</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.039</ci_lower_limit>
            <ci_upper_limit>0.418</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Recording of AEs included periods before first application and until the end of application of study medication. Occurrence of AEs was recorded from time when patient had given his/her informed consent until the final visit of the main study period (visit 28). By definition, AEs starting in the period after first application until the end of the main period were considered to be ‘treatment-emergent’ AEs. Analysis based on safety population: patients received at least 1 dose of treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>HX575 Epoetin Alfa Hexal AG</title>
          <description>Eligible patients were switched from the comparator to HX575 epoetin alfa Hexal AG in ratio 2:1 to be intravenously (solution for injection i.v.) treated with HX575 in pre-filled syringes for 24 weeks. The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL. Baseline HB value after 24 weeks was required for efficacy analysis at week 28.</description>
        </group>
        <group group_id="E2">
          <title>ERYPO®, Janssen-Cilag</title>
          <description>Eligible patients were randomized and continued to be treated with ERYPO®, Janssen-Cilag in pre-filled syringes intravenously (solution for injection i.v.) for 24 weeks. The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL. Baseline HB value after 24 weeks was required for efficacy analysis at week 28.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemias NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic coronary artery disorders</sub_title>
                <counts group_id="E1" events="24" subjects_affected="17" subjects_at_risk="314"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Rate and rhythm disorders NEC</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="314"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Heart failures NEC</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmias</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmias and cardiac arrest</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Coronary artery disorders NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Aortic valvular disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Cardiac disorders NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Cardiomyopathies</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Inner ear signs and symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroid disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataracts (excl congenital)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute and chronic pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Gastric ulcers and perforation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Gastritis (excl infective)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Non-site specific gastrointestinal haemorrhages</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Diverticula</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammatory disorders NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Benign neoplasms gastrointestinal (excl oral cavity)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Duodenal ulcers and perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Dyspeptic signs and symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Gastrointestinal and abdominal pains (excl oral and throat)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Gastrointestinal signs and symptoms NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Gastrointestinal spastic and hypermotility disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Gastrointestinal vascular occlusion and infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Haemorrhoids and gastrointestinal varices (excl oesophageal)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Inguinal hernias</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Intestinal ulcers and perforation NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Nausea and vomiting symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Peritoneal and retroperitoneal disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Peritoneal and retroperitoneal haemorrhages</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile disorders</sub_title>
                <description>General disorders and administrative site conditions</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Implant and catheter site reactions</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Body temperature perception</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Death and sudden death</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>General signs and symptoms NEC</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Healing abnormal NEC</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Trophic disorders</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis and cholelithiasis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Cholestasis and jaundice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Transplant rejections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lower respiratory tract and lung infections</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="314"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Bacterial infections NEC</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Sepsis, bacteraemia and viraemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Infections NEC</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="314"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Abdominal and gastrointestinal infections</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Bone and joint infections</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Streptococcal infections</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Urinary tract infections</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Cardiac infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Influenza viral infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pseudomonal infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Skin structures and soft tissue infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Staphylococcal infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infections</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Vascular infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Viral infections NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cardiac and vascular procedural complications</sub_title>
                <counts group_id="E1" events="27" subjects_affected="24" subjects_at_risk="314"/>
                <counts group_id="E2" events="18" subjects_affected="14" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Lower limb fractures and dislocations</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Non-site specific procedural complications</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Cerebral injuries NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Fractures and dislocations NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Limb injuries NEC (incl traumatic amputation)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Device failure and malfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Device related complications</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Non-site specific injuries NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Site specific injuries NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Thoracic cage fractures and dislocations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Upper limb fractures and dislocations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Urinary tract procedural complications</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Carbohydrate tolerance analyses (incl diabetes)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>ECG investigations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Gastrointestinal histopathology procedures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemic conditions NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Calcium metabolism disorders NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus (incl subtypes)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Total fluid volume increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthropathies</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Arthropathies NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue signs and symptoms NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Myopathies</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colonic neoplasms malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Laryngeal neoplasms malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Metastases to specified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Rectal neoplasms malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Renal cell carcinomas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Respiratory tract small cell carcinomas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Skin neoplasms malignant and unspecified (excl melanoma)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Soft tissue neoplasms benign NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Central nervous system haemorrhages and cerebrovascular accidents</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="314"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Central nervous system vascular disorders NEC</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Seizures and seizure disorders NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Coma states</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Disturbances in consciousness NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Mononeuropathies</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Paralysis and paresis (excl congenital and cranial nerve)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion and disorientation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Depressive disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal disorders NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Bladder infections and inflammations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Renal obstructive disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Renal vascular and ischaemic conditions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm and obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pneumothorax and pleural effusions NEC</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pulmonary oedemas</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Breathing abnormalities</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract inflammatory and immunologic conditions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Respiratory failures (excl neonatal)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Nasal disorders NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Parenchymal lung disorders NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombotic and embolic conditions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue ulcerations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Dermal and epidermal conditions NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Rashes, eruptions and exanthems NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Arterial therapeutic procedures (excl aortic)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Vascular therapeutic procedures NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Joint therapeutic procedures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral vasoconstriction, necrosis and vascular insufficiency</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="314"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Accelerated and malignant hypertension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Aneurysms and dissections non-site specific</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Non-site specific necrosis and vascular insufficiency NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Vascular hypertensive disorders NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Vascular hypotensive disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Peripheral embolism and thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Haemorrhages NEC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Site specific necrosis and vascular insufficiency NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Vena caval embolism and thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="283" subjects_at_risk="314"/>
                <counts group_id="E2" subjects_affected="154" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="85" subjects_affected="63" subjects_at_risk="314"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="36" subjects_affected="27" subjects_at_risk="314"/>
                <counts group_id="E2" events="21" subjects_affected="18" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="43" subjects_affected="30" subjects_at_risk="314"/>
                <counts group_id="E2" events="20" subjects_affected="14" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="73" subjects_affected="55" subjects_at_risk="314"/>
                <counts group_id="E2" events="41" subjects_affected="35" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="34" subjects_affected="28" subjects_at_risk="314"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Haemodialysis-induced symptom</sub_title>
                <counts group_id="E1" events="224" subjects_affected="49" subjects_at_risk="314"/>
                <counts group_id="E2" events="100" subjects_affected="23" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" events="137" subjects_affected="44" subjects_at_risk="314"/>
                <counts group_id="E2" events="60" subjects_affected="23" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Procedural hypertension</sub_title>
                <counts group_id="E1" events="76" subjects_affected="16" subjects_at_risk="314"/>
                <counts group_id="E2" events="39" subjects_affected="10" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="314"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="276" subjects_affected="77" subjects_at_risk="314"/>
                <counts group_id="E2" events="86" subjects_affected="38" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="314"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Shoulder pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="314"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="53" subjects_affected="29" subjects_at_risk="314"/>
                <counts group_id="E2" events="20" subjects_affected="13" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="314"/>
                <counts group_id="E2" events="25" subjects_affected="14" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="314"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="142" subjects_affected="48" subjects_at_risk="314"/>
                <counts group_id="E2" events="26" subjects_affected="20" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="62" subjects_affected="29" subjects_at_risk="314"/>
                <counts group_id="E2" events="17" subjects_affected="9" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Biopharmaceutical Clinical Development, Strategic Planning</name_or_title>
      <organization>Sandoz</organization>
      <phone>0049 80244760</phone>
      <email>biopharma.clinicaltrials@sandoz.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

